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Background: Oxytocin is widely used for the prevention of postpartum haemorrhage. In the 
setting of Caesarean section (CS), the dosage and mode of administrating oxytocin differs 
according to different guidelines. Inappropriate oxytocin doses have been identified as 
contributory to some cases of maternal deaths. The main aim of this study was to audit the 
current standard of clinical practice with regard to the use of oxytocin during CS at a referral 
hospital in Botswana.
Methods: A clinical audit of pregnant women having CS and given oxytocin at the time of 
the operation was conducted over a period of three months. Data included indications for CS, 
oxytocin dose regimen, prescribing clinician’s designation, type of anaesthesia for the CS and 
estimated blood loss.  
Results: A total of 139 case records were included. The commonest dose was 20 IU infusion 
(31.7%). The potentially dangerous regimen of 10 IU intravenous bolus of oxytocin was used 
in 12.9% of CS. Further doses were utilized in 57 patients (41%). The top three indications for 
CS were fetal distress (36 patients, 24.5%), dystocia (32 patients, 21.8%) and a previous CS 
(25 patients, 17.0%). Estimated blood loss ranged from 50 mL – 2000 mL. 
Conclusion: The use of oxytocin during CS in the local setting does not follow recommended 
practice. This has potentially harmful consequences. Education and guidance through evidence 
based national guidelines could help alleviate the problem. 
Introduction
The United Nations’ Millennium Development Goals (MDG) initiative set specific targets to 
improve health and development in developing countries. The fifth MDG targets the reduction of 
maternal mortality by 75% by the year 2015.1 The leading causes of maternal deaths in Africa are 
haemorrhage (33.9%), infection (9.7%) and hypertensive disorders (9.1%).2 In South Africa, obstetric 
haemorrhage is the third commonest cause of maternal death.3 Reports from Botswana highlight 
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L’utilisation d’ocytocine au cours des césariennes à l’hôpital Princess Marina, au Botswana: 
audit de pratique clinique
Contexte: L’ocytocine est couramment utilisée pour la prévention de l’hémorragie post-partum. 
Lors d’une césarienne, le dosage et le mode d’administration de l’ocytocine diffèrent d’une 
directive à l’autre. Des doses inappropriées d’ocytocine ont été identifiées comme contribuant 
à certains cas de décès maternels. Le principal objectif de cette étude était d’évaluer la norme 
actuelle de pratique clinique concernant l’utilisation d’ocytocine pendant une césarienne dans 
un hôpital de référence au Botswana.
Méthodologie: Un audit clinique de femmes enceintes ayant subi une césarienne, et à qui 
on a administré de l’ocytocine au moment de l’opération, a été réalisé sur une période de 
trois mois. Les données comprennent les indications de césarienne, la posologie d’ocytocine, 
la désignation du clinicien prescripteur, le type d’anesthésie pratiqué pour la césarienne et 
l’estimation de la perte de sang. 
Résultats: Un total de 139 cas a été enregistré. La dose la plus courante était une perfusion 
de 20 UI (31.7%). La posologie potentiellement dangereuse de 10 UI d’ocytocine par injection 
intraveineuse a été utilisée dans 12.9% des césariennes. Des doses supplémentaires ont été 
utilisées chez 57 patientes (41%). Les trois premières indications pour la césarienne étaient 
la souffrance fœtale (36 patients, 24.5%), la dystocie (32 patients, 21.8%) et une précédente 
césarienne (25 patients, 17%). La perte de sang estimée était comprise entre 50 mL et 2000 mL. 
Conclusion: L’utilisation d’ocytocine au cours d’une césarienne dans le contexte local ne suit 
pas la pratique recommandée. Les conséquences sont potentiellement dommageables. Une 
éducation et des conseils fournis par des directives nationales avérées pourraient contribuer à 
atténuer le problème.
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that in 2009 a total of 86 maternal deaths were recorded in 
the country. The leading causes were obstetric haemorrhage 
(15.1%), unspecified HIV-related disease (12.8%) and genital 
tract or pelvic infections (8.1%).4
Botswana has a relatively high maternal mortality rate for a 
middle income country (330 per 100 000) and Botswana is 
not on a trajectory to meet the fifth MDG (38 per 100 000) 
despite 98% of deliveries occurring in health facilities across 
the country.1,5 Factors that contribute to maternal morbidity 
and mortality need to be identified and managed in clinical 
practice to achieve the MDG.
Although oxytocin is widely used in obstetrics, it has 
been linked with maternal morbidity and mortality. The 
complications associated with oxytocin include fetal hypoxia, 
hyperstimulation of the uterus and uterine rupture.6 When 
given as an intravenous bolus, oxytocin causes transient 
hypotension, reflex tachycardia and an increase in cardiac 
output in a dose-related manner.6,7,8,9,10,11 
Apart from being a preventive measure, the use of oxytocin 
in the perioperative obstetric patient may paradoxically 
contribute to maternal morbidity and mortality.12 The 
recognition of the potential harm of oxytocin during childbirth 
has resulted in debate about the appropriate dosing of the 
drug. Recent research has identified the optimal intravenous 
dose that balances the risk of side effects with the benefit of 
preventing post-CS haemorrhage as 3–5 IU after delivery of 
the baby, as a single prophylactic dose for all cases.13,14,15,16
The Royal College of Obstetricians and Gynaecologists and 
the National Institute for Health and Clinical Excellence 
recommend 5 IU intravenous bolus to maintain uterine 
contraction during caesarean delivery, consistent with the 
licensed dose for the drug.17,18,19 However, studies continue 
to provide evidence for use of even lower doses of oxytocin 
than those endorsed by current guidelines.12,13,14,15,19
Furthermore, there appears to be no consensus regarding 
the optimal infusion rate of oxytocin needed to prevent 
haemorrhage at CS.8,20,21,22 The World Health Organisation 
(WHO) recommends infusing 20 IU in one litre of crystalloid 
giving 60 drops per minute over two hours as prophylaxis 
against bleeding caused by uterine atony during CS.23
A survey of 240 obstetric anaesthetists in the UK revealed that 
87% of the 179 respondents gave 10 IU oxytocin at CS and 
50% of them gave this by rapid bolus.24 A survey conducted 
in other countries demonstrated that up to 14% of clinicians 
used a 10 IU bolus oxytocin.25 The Confidential Enquiry 
into Maternal Deaths in the UK identified the use of 10 IU 
intravenously as a cause of death during the resuscitation of a 
hypovolaemic patient during CS in the period 1997–1999.12,26 
In South Africa, two maternal deaths have recently been 
linked to the use of high doses of oxytocin.26
Key focus
The rates of CS are increasing internationally and are 
accompanied by a relative increase in the use of uterotonic 
drugs like oxytocin.27,28,29,30 Although oxytocin is used 
routinely, there appears to be variation in its use beyond 
the recommended approach.24,25,26,31 This variation is likely 
to pose a risk. It may contribute to maternal deaths and 
therefore remains a cause for concern.
The current standard of practice with regard to the use of 
oxytocin during CS at Princess Marina Hospital (PMH) 
has never been assessed. There are no protocols in place to 
guide prescribers. The aim of this study was to gauge the 
current standard of practice in the local setting against best 
practice and establish a baseline for recommending good 
clinical practice. 
Objectives 
Research on the use of oxytocin continues to reveal that 
historically high doses of more than 5 IU are not necessary for 
maintaining uterine contraction post-CS as lower doses are 
as effective. Lower doses offer the advantage of posing less 
side effects. The main objective of this study is to assess what 
the standard of practice is with regard to the use of oxytocin 
during CS in the local setting where medical officers, nurse 
and specialist anaesthetists, obstetricians and gynaecologists 
are involved in the use of the drug. This will be established 
by documenting the doses of oxytocin used during CS at 
PMH and the routes of administering these. Furthermore, the 
study seeks to establish and document the average estimated 
blood loss (EBL) during CS where oxytocin was prescribed 
at PMH and report the relationship of these two variables. 
The indications for CS where oxytocin was prescribed will be 
assessed. Additionally, the types of anaesthesia used during 
CS where oxytocin was also used is assessed. The standard of 
practice of oxytocin used around the time of CS is compared 
with international best practice guidelines as outlined above.
Contribution to field
The dangers of high oxytocin doses were highlighted following 
a maternal death in the UK in which oxytocin was a possible 
significant contributory. There has been pressure ever since 
to reduce the oxytocin dose and provide evidence of efficacy 
of a lower dose. There is a body of literature on oxytocin 
guidelines from the WHO and professional bodies, but there 
is little available on implementation and compliance with the 
guidelines. This paper attempts to fill this gap.
Ethical consideration
Ethical approval was obtained from the Health Research Ethics 
Committee at the University of Stellenbosch and the Research 
Ethics Committees of the Botswana Ministry of Health and 
the PMH. A waiver of patient consent was obtained since 
the study only required examination of routinely maintained 
medical records.
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Method
Study design
The study design is a clinical audit of current practice 
involving a case record review of routinely maintained 
medical records. 
Context of the study 
PMH is one of three major public referral hospitals in 
Botswana. It is located in the capital city of Gaborone and 
provides essential obstetric service for a population of over 
191 000 residents. Additionally, PMH receives referrals 
from primary and secondary health facilities in the southern 
part of Botswana, a catchment population of about one 
million people. In Botswana, the various clinicians directly 
involved with the use of oxytocin during CS include medical 
officers, anaesthetic nurses, obstetricians and anaesthetists. 
A dedicated obstetrics and gynaecology theatre is operational 
on a 24-hour basis catering for emergency and elective 
operations. Medical officers (non-specialists) in the department 
of obstetrics and gynaecology work on a rotational basis to 
perform CS at the hospital. Anaesthesia is similarly offered 
by the anaesthetic department’s medical officers, anaesthetic 
nurses and specialists. On average, 128 CS are performed out 
of a total of 540 monthly deliveries at PMH.
All post-CS mothers are admitted to one ward with an 
average length of stay of about three days. Case records, 
including anaesthetic records, are kept in the ward until the 
patient is discharged. 
Selection and sampling of patients
The study was conducted between 01 March and 31 May 
2011. Data were transcribed from case records of all women 
admitted to the post-natal ward following a CS done at PMH, 
where oxytocin was used during and after the operation.
Data collection
We reviewed case notes of all post-CS patients admitted to 
the ward. These were identified from the admission register 
kept in the ward and cross-checked with the theatre record. 
The medication chart, operative notes and anaesthetic record 
were all reviewed. Only case notes where oxytocin had been 
prescribed were included.
A structured data collection form was developed to gather 
information on age, oxytocin dose, route of administration, 
whether further doses of uterotonics were used, indication 
for CS, whether the CS was elective or an emergency, type 
of anaesthesia, estimated blood loss (EBL) and prescriber’s 
designation. The information was transcribed into the data 
collection form and later into an electronic spreadsheet 
(MS Excel).
Where there was more than one indication for CS recorded 
in the case notes, all were noted as separate indications in 
the results. Dystocia was taken to include cephalopelvic 
disproportion, delayed first and second stage of labour and 
failed vacuum extraction. 
Data analysis
Descriptive statistics such as frequencies, means and percentages 
were used for the analysis of the pooled data. Estimated blood 
loss and oxytocin dose were compared using regression and 
Spearman’s correlation analysis.
Results
A total of 139 mothers out of the 145 mothers prescribed 
oxytocin during CS were included in the study with a mean 
maternal age of 28.9 years (a range of 16–43 years). Six 
mothers were excluded due to insufficient documentation. 
Out of these operations, 24 (17.3%) were elective and 115 
(82.7%) were emergency. General anaesthesia was the most 
popularly used, accounting for 64%, whilst spinal anaesthesia 
accounted for the other 36% (Table 1). For emergency CS, 
general anaesthesia was used in 81 per 115 (70.4%) of mothers 
compared to 8 per 24 (33.3%) of elective CS. Use of epidural 
anaesthesia was not reported.
The top three indications for CS were fetal distress (36 
patients, 24.5%), dystocia (32 patients, 21.8%) and a previous 
CS (25 patients, 17.0%) (Table 2). One CS was performed for 
poor maternal effort - a reason not usually recognized as a 
standard indication for CS. Where multiple indications were 
recorded, all were noted as separate indications and the 
percentage shown is out of all 147 indications. No maternal 
deaths were recorded during the study.
The indications for CS differed according to whether the CS 
was an emergency or elective operation (Tables 3 & Table 4). 
Percentages are calculated from the total number of indications 
recorded.
TABLE 1: Type of anaesthesia in emergency and elective Caesarean section.
Anaesthesia Elective (N = 24) Emergency (N = 115) Total (N =139)
n % n % n %
Spinal 16 11.5 34 24.5 50 36.0
General 8 5.6 81 58.3 89 64.0
N, Given as total number; n, Given as number.
TABLE 2: Indications for Caesarean section (N = 147).
Indication n %
Fetal distress 36 24.5
Dystocia 32 21.8
Previous CS and/or Myectomy 25 17
Antepartum haemorrhage 13 8.8
Malposition (breech, transverse lie) 12 8.2
Failed induction of labour and/or Postdates 10 6.8
Eclampsia and/or Severe pre-eclampsia 6 4.1
Other (multiple fibroids, twins and/or poor maternal effort) 4 2.7
Cord prolapse 3 2
Bad obstetric history 2 1.4
Medical condition 2 1.4
Ruptured uterus 1 0.7
Intrauterine growth restriction 1 0.7
N, Given as total number; n, Given as number.
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Different doses and routes of administration for oxytocin 
were observed (Table 5 & Figure 1). The commonest dose 
used was 20 IU intravenous infusion (31.7%).
Further doses of uterotonics were utilized in 57 of the 
mothers (41%) and this included different doses of oxytocin 
and syntometrine. 
Estimated blood loss ranged from 50 mL – 2000 mL. The mean 
blood loss and the corresponding oxytocin doses prescribed 
(see Table 6). 
Prescribing practices differed widely, with medical officers 
and anaesthetic nurses accounting for all instances where 
the 10 IU intravenous bolus was used (Table 7). Anaesthetic 
nurses accounted for the three times where an intravenous 
bolus of 20 IU bolus was used.
There was a statistically significant relationship between the 
oxytocin dosage used and the estimated blood loss (p = 0.03), 
although the strength of the association was low (r = 0.19). 
The oxytocin dose increased with increasing estimated blood 
loss (Figure 2).
Discussion
The present study revealed that only 30% of users adhered 
to the recommended practice of 5 IU intravenous oxytocin 
at CS. A total of 31.7% of participants in the study used an 
infusion of 20 IU in one litre of a crystalloid solution. As the 
TABLE 3: Indications for emergency Caesarean section (N = 125).
Indication f %
Fetal distress 36 28.8
Dystocia 29 23.2
Previous Caesarean section in labour 14 11.2
Antepartum haemorrhage 13 10.4
Malposition 12 9.6
Eclampsia 6 4.8
Cord prolapse 3 2.4
Postdates 3 2.4
Failed Induction of labour 2 1.6
Medical condition 2 1.6
Ruptured uterus 1 0.8
Intrauterine growth restriction 1 0.8
Bad obstetric history 1 0.8
Twins 1 0.8
Poor maternal effort 1 0.8
Total 125 100
N, Given as total number; n, Given as number; f, Frequency.
TABLE 4: Indications for elective Caesarean section (N = 24).
Indication n %
Previous Caesarean section 12 50
Dystocia 6 25
Postdates 5 20.8
Bad obstetric history 1 4.2
Total 24 100
N, Given as total number; n, Given as number.
TABLE 5: Different dose regimens of oxytocin used (N = 139).
Dose (IU) Route n %
5 IV bolus 41 29.5
10 IV bolus 18 12.9
15 IV bolus 2 1.4
20 IV bolus 3 2.2
10 IV infusion 28 20.1
15 IV infusion 1 0.7
20 IV infusion 44 31.7
30 IV infusion 1 0.7
40 IV infusion 1 0.7
N, Given as total number; n, Given as number.
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FIGURE 1: Different doses and routes of administration of oxytocin.
TABLE 6: Dose of oxytocin used and the estimated blood loss.
Dose Mean blood loss (mL) Blood loss range (mL)
5 IU IV bolus 382 100 − 1500
10 IU IV bolus 346 0 − 900
10 IU IV infusion 320 100 − 900
15 IU IV bolus 350 350
15 IU IV infusion 100 100 − 200
20 IU IV bolus 750 300 − 1200
20 IU IV Infusion 493 100 − 2000
30 IU IV infusion 500 500 − 1200
40 IU IV infusion 500 500
TABLE 7: Oxytocin prescription by different categories of prescribers.
Dose Prescriber f
5 IU IV bolus Anaesthetic nurse 7
 Medical officer 37
 O & G Specialist 1
 Anaesthetist 1
10 IU IV bolus Anaesthetic nurse 2
 Medical officer 16
 O & G Specialist 0
 Anaesthetist 0
10 IU Infusion Anaesthetic nurse 0
 Medical officer 25
 O & G specialist 0
 Anaesthetist 0
20 IU IV bolus Anaesthetic nurse 3
 Medical officer 0
 O & G specialist 0
 Anaesthetist 0
30 IU Infusion Anaesthetic nurse 0
 Medical officer 0
 O & G specialist 1
 Anaesthetist 0
40 IU Infusion Anaesthetic nurse 0
 Medical officer 1
 O & G specialist 0
 Anaesthetist 0
f, Frequency.
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infusion rates were not recorded, it was difficult to say if the 
WHO guideline was followed. 
The low correlation of dosage and EBL suggests that choice 
of dosage is only weakly associated with the perception 
of blood loss and that variation in dose is most likely 
dependent on other factors. One would have expected a 
greater correlation between increasing dose of oxytocin and 
the higher EBL associated with post-partum haemorrhage in 
instances where an initial dose of oxytocin did not arrest the 
bleeding. However, this study did not differentiate between 
whether oxytocin was prescribed for prophylaxis against 
post-partum haemorrhage, or for its management once it had 
been diagnosed. Estimation of blood loss at CS is known to 
vary widely according to a clinician’s perception and may 
have a large subjective element.24 Additionally, the skills and 
experience of the surgeon doing the CS is an important factor 
in the resulting blood loss from the surgery.
The number of oxytocin receptors expressed in the 
myometrium increases as pregnancy advances from 12 weeks 
gestation.32 Following continuous and prolonged exposure 
to oxytocin, there is significant loss in the capacity of the 
myometrial cells to respond as a result of oxytocin receptor 
desensitisation.33,34,35 It is in view of this physiological fact 
that there has been recommendations to consider other 
uterotonics where additional doses of oxytocin prove not to 
adequately control haemorrhage since these alternatives are 
not affected by the desensitation.6,26
The high proportion of emergency to elective CS noted is 
likely due to the fact that high risk pregnancies are referred 
to PMH as emergencies. 
Fetal distress (FD) was the commonest indication overall for 
CS and emergency CS where oxytocin was used, contributing 
25% and 28.2% respectively. Although this study looked at a 
subset of women who were prescribed oxytocin during CS and 
not all women who had CS, the percentages regarding FD 
appear high. International studies suggest that rates for FD 
as an indication for CS were as low as 6% –17% in Ghana and 
as high as 46% in the UK for repeated emergency CS.36,37
The significant contribution of FD as an indication for CS in 
our study begs the question of whether this entity is accurately 
diagnosed, since the diagnosis is made on observation of fetal 
heart rate on cardiotocograph. Despite the high sensitivity of 
cardiotocograph in detecting FD, it has a high rate of false 
positives, as well as inter- and intra-observer variation.38 
The rates of general anaesthesia used during the study 
appear higher than in other African countries such as Nigeria, 
which reported a rate of 47.6%.39 The high uptake of general 
anaesthesia as opposed to regional anaesthesia in this study 
potentially increases the risk of anaesthesia-related causes of 
maternal morbidity and mortality since general anaesthesia 
is a recognised risk for most direct anaesthetic deaths.40
Limitaions and strengths of the study
The unique setting of PMH that provides local district 
hospital type services and regional referral hospital services 
with a high volume of patients, presents a peculiar advantage 
in conducting this study. A variety of users were represented 
in the study with the majority being non-specialists - a 
situation closer in reality to the staff compliment of primary 
and district hospitals in Botswana.
The study did not identify specific individuals (but rather 
groups) who prescribed specific doses and thus potentially 
harmful practice could not be linked to specific individuals. 
However, this is useful in not creating a climate of blame - a 
clear objective of clinical audit.
The study could not distinguish whether oxytocin was 
primarily given as prophylaxis or treatment nor what 
the infusion rate was, since this was not stated in the case 
records from which data was transcribed. This highlights the 
fact that patient notes were not being adequately recorded. 
The deficiency in data could have been addressed better in a 
prospective study.
Practical implications and recommendations
The effort to improve the current clinical practice with regard 
to the use of oxytocin during CS in the local setting, could 
include developing a national protocol for prophylactic use 
of oxytocin at CS. Junior doctors, anaesthetic nurses and non-
specialist doctors should be targeted for continuing medical 
education activities that include training on the appropriate 
use of oxytocin at CS. This should also be addressed in the 
initial training of these clinicians and that of family physicians 
as they rotate through the departments of Obstetrics and 
Anaesthetics at PMH and other centres.
A re-audit of clinical practice after implementation of the 
protocol and appropriate education should be done.
Conclusions
The use of oxytocin during CS in the local setting does 
not generally follow recommended practice and current 
literature. This has potentially harmful consequences, such as 
increased maternal morbidity and mortality. Education and 
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guidance by national practice guidelines and local protocols 
could help alleviate the problem. This audit could be used as 
a baseline for future assessment of clinical practice at PMH 
and as a stimulus for similar clinical audits in other centres. 
Acknowledgements
The authors wish to thank prof. Martin Kidd (statistical 
assistance), Prof. Sunanda Ray and dr Luise Parsons for their 
support in developing this work.
Competing interest
The authors declare that they have no financial or personal 
relationship(s) which may have inappropriately influenced 
them in writing this article.
Authors’ contributions
B.T. (Stellenbosch University) and F.M. (University of 
Botswana) conceived the idea for the study. B.T. was principle 
investigator and collected the data. B.M. (Stellenbosch 
University) contributed to further development of the 
concept. B.T. wrote the manuscript, whilst F.M. and B.M. 
provided editorial comments.
References
1. United Nations Development Group. National MDG reports. [homepage on the 
Internet]. July 2008 [cited 2011 April 19]. Available from http://www.undg.org/
index.cfm?P=87&f=B 
2. Khan K, Wojdyla D, Say L, et al. WHO analysis of causes of maternal death: a 
systemic review. Lancet. 2006;367:1066–1074. http://dx.doi.org/10.1016/S0140-
6736(06)68397-9
3. Fawcus S, Moodley J. Haemorrhage associated with caesarean section - be aware. 
S Afr Med J. 2011;101(5):306–309. PMid:21837869
4. Central Statistics Office. Health Statistics [homepage on the internet]. 2011 [cited 
2011 July 11]. Available from: http://www.cso.gov.bw 
5. Central Statistics Office. Botswana Multiple Indicator Survey. Gaborone: Government 
Printers; 2001.
6. Langesaeter E, Rosseland L, Stubhaug A. Haemodynamic effects of repeated 
dose of oxytocin during Caesarean delivery in healthy parturients. Br J Anaesth. 
2009;103(2):260–262. http://dx.doi.org/10.1093/bja/aep137, PMid:19502285
7. Pinder AJ, Dresner C, Calow G, et al. Haemodynamic changes caused by oxytocin 
during caesarean section under spinal anaesthesia. Int J obstet Anaesth. 
2002;11:156–159. http://dx.doi.org/10.1054/ijoa.2002.0970, PMid:15321540
8. Thomas JS, Koh S, Cooper G. Haemodynamic effects if oxytocin given as i.v. bolus 
or in fusion on women undergoing Ceasarean section. BJA. 2007;98:116–119. 
http://dx.doi.org/10.1093/bja/ael302, PMid:17142825
9. Jonsson M, Hanson U, Lindell C, et al. ST depression at Caesarean section and 
the relation to oxytocin dose. A randomised control trial. BJOG. 2010;117:76–83. 
http://dx.doi.org/10.1111/j.1471-0528.2009.02356.x, PMid:19781043
10. Connell JE, Mahomed K. Medical methods for preventing blood loss at Caesarean 
section (protocol). The Cochrane Database Syst Rev. 2009;1:CD007576.
11. Basson E, Odendaal HJ, Grove D. Oxytocin use in South Africa - a review. S Afr Med 
J. 2004;94:839–845. PMid:15532761
12. Cooper GM, Lewis G, Neilson J. Confidential enquiries into maternal deaths. 
1997–1999. Br J Anaesth. 2002;89:369–372. http://dx.doi.org/10.1093/bja/aef194, 
PMid:12402712
13. Calvalho JC, Balki M, Kingdom J, Windrim R. Oxytocin requirements at elective 
Cesarean delivery: a dose-finding study. Obstet Gynecol. 2004;104:1005–1010. 
http://dx.doi.org/10.1097/01.AOG.0000142709.04450.bd, PMid:15516392
14. Butwick AJ, Coleman L, Cohen SE, et al. Minimum effective bolus dose of oxytocin 
during elective Caesarean delivery. Br J Anaesth. 2010;104:338–343. http://
dx.doi.org/10.1093/bja/aeq004, PMid:20150347
15. Sartain JB, Barry JJ, Howat PW, et al. Intravenous oxytocin bolus of 2 units is superior 
to 5 units during elective Caesarean section. Br J Anaesth. 2008;101(6):822–826. 
http://dx.doi.org/10.1093/bja/aen273, PMid:18845650
16. Balki M, Ronayne M, Davis S, et al. Minimum oxytocin dose requirement after 
Cesarean delivery for labor arrest. Obstet Gynaecol. 2006;107:45–50. http://
dx.doi.org/10.1097/01.AOG.0000191529.52596.c0, PMid:16394038
17. Royal College of Obstetricians and Gynaecologists. Postpartum haemorrhage, 
prevention and management (Green-top Guideline 52) [homepage on the internet]. 
2009 May 11 [cited 2011 April 20]. Available from http://rcog.org.uk/guidelines 
18. National Institute for Health and Clinical Excellence. Caesarean Section [homepage 
on the internet]. 2009 June 15 [cited 2011 April 19]. Available from http://www.
nice.org.uk/nicemedia/live/10940/29334/29334.pdf 
19. British Medical Association. Royal Pharmaceutical Society of Great Britain British 
National Formulary. London; 2003.
20. Dyer RA, Butwick AJ, Carvalho B. Oxytocin for labour and Caesarean delivery: 
implications for the anaesthesiologist. Curr Opin Anaesth. 2011;24:255–261. 
http://dx.doi.org/10.1097/ACO.0b013e328345331c, PMid:21415725
21. Sarna MC, Soni AK, Gomez M, Oriol NE. Intravenous oxytocin in patients undergoing 
elective Caesarean section. Anesth Analg. 1997;84(4):753–756. PMid:9085952
22. George RB, Mackeen D, Chaplin AC, Mcleod L. Up-down determination of the 
ED90 of oxytocin infusions for the prevention of postpartum uterine atony in 
parturients undergoing Caesarean delivery. Can J Anaesth. 2010;57(6):578–582. 
http://dx.doi.org/10.1007/s12630-010-9297-1, PMid:20238255
23. World Health Organisation. Managing complications in pregnancy and childbirth: 
A guide for midwives and doctors. World Health Organisation; 2007.
24. Wedisinghe L, Macleod M, Murphy DJ. Use of oxytocin to prevent haemorrhage 
at Ceasarean section - a survey of practice in the United Kingdom. Gynaecol 
Reprod Biol. 2008;137:27–30. http://dx.doi.org/10.1016/j.ejogrb.2007.04.007, 
PMid:17544563
25. Sheehan SR, Wedisinghe L, Macleod M, Murphy DJ. Implementation of guidelines 
on oxytocin use at Caesarean section: A survey of practice in the British Isles. 
Intern J Gyne & Obst. 2009;107:336.
26. Dyer RA, van Dyk D, Dresner A. The use of uterotonic drugs during Caesarean 
section. Inter J Obstet Anaesth. 2010;19:313–319. 
27. Betran AP, Merialdi M, Lauer JA, et al. Rates of Caesarean section: analysis of global, 
regional and national estimates. Paediatr Perinat Epidemiol. 2007;21(2):98–113. 
http://dx.doi.org/10.1111/j.1365-3016.2007.00786.x, PMid:17302638
28. Althabe F, Sosa C, Belizan JM, et al. Caesarean section rates and maternal and 
neonatal mortality in low-, medium- and high-income countries: an ecological study. 
Birth. 2006;33(4):270–271. http://dx.doi.org/10.1111/j.1523-536X.2006.00118.x, 
PMid:17150064
29. Naidoo RP, Moodley J. Rising rates of Caesarean sections: An audit of Caesarean 
sections in a specialist private practice. SA Fam Pract. 2009;51(3):254–258.
30. Nula M, Thinkhamprop J, Seejorn K, et al. Rising Caesarean delivery rates at a 
tertiary care centre in Thailand. Inter J Gynaecol Obstet. 2010;110(1):76–77. 
http://dx.doi.org/10.1016/j.ijgo.2010.03.006, PMid:20394924
31. Bolton TJ, Randall K, Yentis SM. Effects of the confidential enquiries into maternal 
deaths on the use of syntocinon at Caesarean section in the UK. Anaesth. 
2003;58:261–279. http://dx.doi.org/10.1046/j.1365-2044.2003.30435.x
32. Kimura T, Takemura M, Nomura S, et al. Expression of oxytocin receptors in human 
pregnant myometrium. Endocrine Journal. 1996;137:780–785. http://dx.doi.org/ 
10.1210/en.137.2.780
33. Glimpl G, Fahrenholtz F. The oxytocin receptor system: structure, function and 
regulation.  Physiological Reviews. 2001;81(2):629–683.
34. Arias F. Pharmacology of oxytocin and prostagladins. Clin Obstet Gynecol. 
2000;43:455–468. http://dx.doi.org/10.1097/00003081-200009000-00006, 
PMid:10949750
35. Phaneuf S, Asboth G, Carrasco MP, et al. The desensitation of oxytocin receptors in 
human myometrial cells is accompanied by down-regulation of oxytocin receptor 
messenger RNA. Endocrine Journal. 1997;154:7–18. http://dx.doi.org/10.1677/
joe.0.1540007
36. Kwawukume EY. Caesarean section in developing countries. Best Pract Research: 
Clinical Obstet Gynae. 2001;15(1):165–172. http://dx.doi.org/10.1053/beog.2000.0155, 
PMid:11359321
37. Wasef WRK. An audit of trial of labour after previous Caesarean section. J Obstet 
Gynaecol. 2000;20(4):380–381. http://dx.doi.org/10.1080/01443610050112002, 
PMid:15512590
38. Davane D, Lalor J. Midwives visual interpretation of intrapartum cardiotograph 
intra- and inter-observer agreement. J Adv Nurs. 2005;52(2):133–141. http://
dx.doi.org/10.1111/j.1365-2648.2005.03575.x, PMid:16164474
39. Okafar UV, Ezegwui HU, Ekwazi K. Trends of different forms of anaesthesia for 
Caesarean section in South-Eastern Nigeria. J Obstet Gynaecol. 2009;29(5):392–395. 
http://dx.doi.org/10.1080/01443610902932390, PMid:19603315
40. Dresser MR, Freeman JM. Anaesthesia for Caesarean section. Best Pract Research: 
Clinical Obstet Gynae. 2001;15(1):127–143. http://dx.doi.org/10.1053/beog.2000.0153, 
PMid:11359319
